InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
NantKwest is an innovative clinical-stage immunotherapy company focused on harness...
NantKwest is an innovative clinical-stage immun...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...
Spectrum Pharmaceuticals is a leading biotechno...
Celyad is a biopharmaceutical company, specialized in CAR-T cell therapy, that is ...
Celyad is a biopharmaceutical company, speciali...
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focu...
Paratek Pharmaceuticals, Inc. is a commercial-s...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
Caladrius is a clinical-stage biopharmaceutical company committed to the developme...
Caladrius is a clinical-stage biopharmaceutical...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...
argenx is a clinical-stage biotechnology compan...
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...
Arena Pharmaceuticals is driven to deliver nove...
Join the National Investor Network and get the latest information with your interests in mind.